Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Antagonism of the Thromboxane-Prostanoid Receptor as a Potential Therapy for Cardiomyopathy of Muscular Dystrophy.

West JD, Galindo CL, Kim K, Shin JJ, Atkinson JB, Macias-Perez I, Pavliv L, Knollmann BC, Soslow JH, Markham LW, Carrier EJ.

J Am Heart Assoc. 2019 Nov 5;8(21):e011902. doi: 10.1161/JAHA.118.011902. Epub 2019 Oct 30.


Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.

Chun JL, O'Brien R, Song MH, Wondrasch BF, Berry SE.

Stem Cells Transl Med. 2013 Jan;2(1):68-80. doi: 10.5966/sctm.2012-0107. Epub 2012 Dec 27. Erratum in: Stem Cells Transl Med. 2013 Feb;2(2):following 158.


Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice.

Ballmann C, Denney TS, Beyers RJ, Quindry T, Romero M, Amin R, Selsby JT, Quindry JC.

Am J Physiol Heart Circ Physiol. 2017 Jan 1;312(1):H128-H140. doi: 10.1152/ajpheart.00552.2016. Epub 2016 Nov 11.


Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.

Gutpell KM, Hrinivich WT, Hoffman LM.

PLoS One. 2015 Jan 21;10(1):e0117306. doi: 10.1371/journal.pone.0117306. eCollection 2015.


Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system.

Sabharwal R, Chapleau MW.

Exp Physiol. 2014 Apr;99(4):627-31. doi: 10.1113/expphysiol.2013.074336. Epub 2013 Dec 13. Review.


Intolerance to ß-blockade in a mouse model of δ-sarcoglycan-deficient muscular dystrophy cardiomyopathy.

Bauer R, Blain A, Greally E, Bushby K, Lochmüller H, Laval S, Straub V, MacGowan GA.

Eur J Heart Fail. 2010 Nov;12(11):1163-70. doi: 10.1093/eurjhf/hfq129. Epub 2010 Jul 30.


Oxidized CaMKII (Ca2+/Calmodulin-Dependent Protein Kinase II) Is Essential for Ventricular Arrhythmia in a Mouse Model of Duchenne Muscular Dystrophy.

Wang Q, Quick AP, Cao S, Reynolds J, Chiang DY, Beavers D, Li N, Wang G, Rodney GG, Anderson ME, Wehrens XHT.

Circ Arrhythm Electrophysiol. 2018 Apr;11(4):e005682. doi: 10.1161/CIRCEP.117.005682.


Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.

Delfín DA, Zang KE, Schill KE, Patel NT, Janssen PM, Raman SV, Rafael-Fortney JA.

Neuromuscul Disord. 2012 Nov;22(11):1006-14. doi: 10.1016/j.nmd.2012.05.002. Epub 2012 Jun 29.


Transient receptor potential channel 6 regulates abnormal cardiac S-nitrosylation in Duchenne muscular dystrophy.

Chung HS, Kim GE, Holewinski RJ, Venkatraman V, Zhu G, Bedja D, Kass DA, Van Eyk JE.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10763-E10771. doi: 10.1073/pnas.1712623114. Epub 2017 Nov 29.


Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.

van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, 't Hoen PA, Aartsma-Rus A.

Neuromuscul Disord. 2012 May;22(5):406-17. doi: 10.1016/j.nmd.2011.10.011. Epub 2012 Jan 27.


Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.

Gibertini S, Zanotti S, Savadori P, Curcio M, Saredi S, Salerno F, Andreetta F, Bernasconi P, Mantegazza R, Mora M.

Cell Tissue Res. 2014 May;356(2):427-43. doi: 10.1007/s00441-014-1854-4. Epub 2014 Apr 11.


Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Wasala NB, Bostick B, Yue Y, Duan D.

Hum Mol Genet. 2013 Jul 1;22(13):2634-41. doi: 10.1093/hmg/ddt112. Epub 2013 Mar 3.


Blunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy.

Li Y, Zhang S, Zhang X, Li J, Ai X, Zhang L, Yu D, Ge S, Peng Y, Chen X.

Cardiovasc Res. 2014 Jul 1;103(1):60-71. doi: 10.1093/cvr/cvu119. Epub 2014 May 8.


Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy.

Blain A, Greally E, Laval S, Blamire A, Straub V, MacGowan GA.

PLoS One. 2013;8(2):e57260. doi: 10.1371/journal.pone.0057260. Epub 2013 Feb 20.


Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice.

Zhou L, Rafael-Fortney JA, Huang P, Zhao XS, Cheng G, Zhou X, Kaminski HJ, Liu L, Ransohoff RM.

J Neurol Sci. 2008 Jan 15;264(1-2):106-11. Epub 2007 Sep 24.


Increased constitutive nitric oxide production by whole body periodic acceleration ameliorates alterations in cardiomyocytes associated with utrophin/dystrophin deficiency.

Lopez JR, Kolster J, Zhang R, Adams J.

J Mol Cell Cardiol. 2017 Jul;108:149-157. doi: 10.1016/j.yjmcc.2017.06.004. Epub 2017 Jun 13.


Nitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters.

Ramachandran J, Schneider JS, Crassous PA, Zheng R, Gonzalez JP, Xie LH, Beuve A, Fraidenraich D, Peluffo RD.

Biochem J. 2013 Jan 1;449(1):133-42. doi: 10.1042/BJ20120787.


Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice.

Li D, Long C, Yue Y, Duan D.

Hum Mol Genet. 2009 Apr 1;18(7):1209-20. doi: 10.1093/hmg/ddp015. Epub 2009 Jan 8.


Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient mouse during development of dilated cardiomyopathy.

Chun JL, O'Brien R, Berry SE.

Neuromuscul Disord. 2012 Apr;22(4):368-79. doi: 10.1016/j.nmd.2011.07.003. Epub 2012 Jan 21.


Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.

Betts CA, McClorey G, Healicon R, Hammond SM, Manzano R, Muses S, Ball V, Godfrey C, Merritt TM, van Westering T, O'Donovan L, Wells KE, Gait MJ, Wells DJ, Tyler D, Wood MJ.

Hum Mol Genet. 2019 Feb 1;28(3):396-406. doi: 10.1093/hmg/ddy346.

Supplemental Content

Support Center